Remove company amerisourcebergen
article thumbnail

Avoiding Commercialization Pitfalls for CGTs

PharmExec

Lung-I Cheng, vice president of cell and gene therapy (CGT), Cencora (formerly AmerisourceBergen), discusses CGT commercialization strategies, common knowledge gaps, and what he wishes companies knew about commercialization strategies.

105
105
article thumbnail

AmerisourceBergen agrees to acquire PharmaLex for $1.29bn

Pharmaceutical Technology

AmerisourceBergen has entered a definitive agreement for the acquisition of PharmaLex from Auctus Capital Partners in a deal worth $1.29bn (€1.28bn) in cash, subject to specific adjustments. The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AmerisourceBergen introduces CGT integration hub

Pharmaceutical Technology

Global healthcare company AmerisourceBergen has launched a cell and gene therapy (CGT) integration hub. The hub will also allow the company to complete platform integrations with supply chain partners, such as CGT software providers and therapy developers.

article thumbnail

AmerisourceBergen aims to make digital therapeutics access easier

pharmaphorum

Pharma distributor AmerisourceBergen is working on a platform to make access to digital therapeutics (DTx) easier in the US by providing a unified system for ordering, dispensing and fulfilment. The post AmerisourceBergen aims to make digital therapeutics access easier appeared first on. billion in 2021.

article thumbnail

Does anyone really believe pharma cares what people think?

World of DTC Marketing

Besides the increased costs of prescription drugs above inflation levels, drug companies are playing a shell game with the opioid settlements. Analysts expect that “big biopharma” companies will collectively have more than $500 billion in cash to deploy by 2022.

Pharma 183
article thumbnail

FDA accepts Outlook Therapeutics’ BLA for wet AMD treatment

Pharmaceutical Technology

In preparation for ONS-5010's anticipated approval and commercial launch, the company has recently entered a strategic commercialisation agreement with AmerisourceBergen. Outlook expects to increase ONS-5010’s market access and efficient distribution through this contract.

article thumbnail

Misjustice benefits pharma

World of DTC Marketing

million doses of oxycodone and hydrocodone to pharmacies in Cabell County and the city of Huntington over less than a decade, McKesson, AmerisourceBergen, and Cardinal Health didn’t cause an oversupply of opioids in the area, Judge David Faber ruled on Monday. Despite distributing more than 51.3 New York Times.

Pharma 238